{"text": "推荐11：胆固醇吸收抑制剂依折麦布和PCSK9抑制剂可作为他汀不耐受或单药治疗LDL-C不能达标时的联合用药(建议；A级证据)。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "不耐受", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "我国肥胖与糖尿病外科(减重代谢外科)事业起源于2000年郑成竹教授开展的第一例腹腔镜垂直胃绑带术，经过近20年的发展，国内开展手术的医院已经超过200家，手术例数近年也呈现快速增长，这是令人可喜也值得欣慰的事。为了指导及规范该学科的健康发展，经过一定的临床实践，中华医学会外科学分会内分泌外科学组联合腹腔镜与内镜外科学组、胃肠外科学组及外科手术学学组分别于2007年和2010年先后制订和颁布了《中国肥胖病外科治疗指南(2007)》及《中国糖尿病外科治疗专家指导意见(2010)》。2012年中国医师协会外科医师分会肥胖和糖尿病外科医师委员会(Chinese Society for Metabolic and Bariatric Surgery，CSMBS)组建成立，2014年11月CSMBS发表了《中国肥胖和2型糖尿病外科治疗指南(2014)》，2014年12月人民卫生出版社出版了《肥胖与代谢病外科学》，旨在规范该学科的发展及应用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前临床应用的胰岛素包括动物胰岛素、人胰岛素及胰岛素类似物。其中，人胰岛素具有免疫原性低、长期使用安全可靠、效价比高等优点，在临床中应用最为广泛，在2型糖尿病血糖管理中作用突出。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "二、减少或延缓微血管及大血管并发症发生和发展的效果", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "大血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管并发症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "6.其他：心率变异度测定可反映副交感神经的功能，是诊断小纤维受累为主周围神经病变的主要方法之一。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "心率变异度测定", "subject_type": "检查方法", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "小纤维", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.血压控制目标：糖尿病患者的血压控制目标为140/90mmHg，对年轻患者或合并肾病者的血压控制目标为130/80mmHg。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.证据来源：本共识以关键词检索当前关CKD合并HUA的相关研究证据，主要关键词包括：慢性肾脏病(chronic kidney disease)、高尿酸血症(hyperuricemia)、指南(guideline)、荟萃分析(met中国生物医学文献数据库(CBM)、中国期刊网全文数据库(CNKI)、万方数据资源系统和中文科技期刊全文数据库(VIP)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病(chronic kidney disease)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在T2DM患者中CVOT证实心血管效应为中性的降糖药物包括罗格列酮、吡格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "罗格列酮", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "吡格列酮", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甘精胰岛素", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "利司那肽", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "T2DM及肥胖确诊后，至少每年评估1次心血管病变的风险因素，评估的内容包括心血管病既往史及现状、年龄、有无心血管风险因素(吸烟、血脂紊乱、高血压和家族史等)、肾脏损害(尿白蛋白排泄率增高等)、心房颤动(可导致卒中)。全面评估和控制心血管疾病风险因素，并进行合理的降压、调脂和抗血小板治疗，可显著改善糖尿病患者心脑血管病变和死亡发生的风险。联合使用其他药物时应注意：β受体阻滞剂增加体重、他汀类药物升高血糖、某些抗抑郁焦虑药物增加体重等。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "评估1次心血管病变的风险因素", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "评估1次心血管病变的风险因素", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白排泄率", "subject_type": "检查指标", "object": {"@value": "肾脏损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "心房颤动", "subject_type": "患病病因", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "降压", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "调脂", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "抗血小板治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "β受体阻滞剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "升高血糖", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(5)β受体阻滞剂：尽管ACEI在降低糖尿病患者蛋白尿方面较β受体阻滞剂更有优势，但两种药物均可延缓患者肾功能的衰退。UKPDS研究亦认为ACEI与β受体阻滞剂在降低2型糖尿病患者微血管和大血管并发症方面临床价值相当。β受体阻滞剂可作为降压治疗的联合用药。第一类为非选择性β受体阻滞剂，主要代表药物是普萘洛尔，目前已较少使用。第二类主要作用于β1受体，代表药物有美托洛尔、比索洛尔。美托洛尔主要经肝脏代谢，5%以原型经肾排泄，用于肾功能损害者剂量无需调整。比索洛尔50%通过肝脏代谢为无活性的代谢产物然后从肾脏排出，剩余50%以原形药的形式从肾脏排出，轻中度肾功能不全患者剂量不需调整，当GFR<20ml·min-1·1.73m-2时每日剂量不超过10mg，肾透析患者使用经验较少。第三类主要作用于β和α1受体，代表药物有卡维地洛、拉贝洛尔。拉贝洛尔55%~60%的原形药物和代谢产物由尿排f也，血液透析和腹膜透析均不易清除，应慎用于肾功能不全者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "β受体阻滞剂", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "ACEI", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "β受体阻滞剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "美托洛尔", "subject_type": "药品名称", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "比索洛尔", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "不超过10mg", "subject_type": "用药剂量", "object": {"@value": "比索洛尔"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "肾透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "拉贝洛尔", "subject_type": "药品名称", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "血液透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "腹膜透析", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "SGLT2i在不同程度肾功能不全的T2DM患者中所进行的研究提示，轻度肾功能不全，此类药物仍然发挥疗效，并具有良好的安全性。中度肾功能不全进一步下降SGLT2i的疗效，逐渐下降直至无明显疗效，但并没有明显的安全性的问题。起始SGLT2i治疗前需检测肾功能，并根据肾功能确认是否可以起始治疗，治疗过程中每年至少监测一次肾功能。治疗过程中，如果同时予以影响肾功能的药物治疗其他疾病时，起始前需监测肾功能，且定期监测肾功能，当患者的肾功能逐渐下降并趋向与中度肾功能不全时，需要每年监测2~4次肾功能同时关注泌尿道感染和血容量降低相关的不良事件。目前，在重度肝功能不全的T2DM数据有限。欧、美国家的药物说明书中不推荐在重度肝功能不全的T2DM中使用SGLT2i。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "SGLT2i", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "监测2~4次肾功能", "subject_type": "检查方法", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病周围神经病(diabetic peripheral neuropathy，DPN)是糖尿病的常见并发症，临床表现包括多种类型，其中以远端对称性多发性周围神经病(distal symmetric polyneuropathy，DSPN)和自主神经病最为常见。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病周围神经病(diabetic peripheral neuropathy，DPN)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "远端对称性多发性周围神经病(distal symmetric polyneuropathy，DSPN)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "自主神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "磺脲类药物治疗常见的不良反应有以下几种：①低血糖：临床上起始磺脲类药物剂量过大，或在肝、肾功能不全患者中的不恰当使用可导致低血糖；单药治疗或与其他降糖药物联合治疗均可能出现低血糖。②体重增加。③磺脲类药物与磺胺类药物可发生交叉过敏反应，有磺胺类药物过敏史者应禁用磺脲类药物。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "交叉过敏反应", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝、肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝、肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在老年糖尿病的治疗中，加强糖尿病教育和管理是重要的理念工程。英国前瞻性糖尿病研究(UKPDS)和糖尿病控制与并发症试验(DCCT)的后续研究给了我们强化血糖控制获得‘代谢记忆’的启示，多个研究显示在糖尿病早期给予的良好血糖控制是患者后期获益的基石(B)。丹麦干预多重危险因素对2型糖尿病微血管病、心血管病、病死率的效果(Steno-2研究)和日本2型糖尿病长期理想血糖控制对糖尿病大血管病变的影响(Kumamoto研究)显示，对糖尿病综合治疗可获得良好结局(B)。由此而言，“早防早治、良好血糖控制、综合控制多项代谢异常”是糖尿病患者的理想治疗原则。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "大血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "代谢异常", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "条件允许时，在起始胰岛素治疗的早期可通过住院密切监测血糖来每天调整胰岛素剂量：根据空腹血糖，调整基础胰岛素剂量1~4单位或10%~20%；根据下一餐前血糖值，调整餐时胰岛素剂量1-2单位或10%。如果出现空腹或夜间低血糖(<3.9毫摩尔/升)或低血糖症状，则应减少基础胰岛素和/或晚餐前的餐时胰岛素剂量10%~20%；如果日间两餐间出低血糖，则减少上一餐的餐时胰岛素剂量10%~20%；如出现需他人协助的严重低血糖或随机血糖<2.2毫摩尔/升，则减少20%~40%胰岛素剂量。", "spo_list": [{"Combined": false, "predicate": "用药剂量", "subject": "1~4单位", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "1-2单位", "subject_type": "用药剂量", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "餐时胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "1.微血管并发症：UKPDS证实，以氯磺丙脲、格列本脲为基础的降糖治疗，可减少新诊断2型糖尿病患者的微血管复合终点风险25%(P=0.0099)，其中视网膜病变风险下降29%(P=0.0031，1b级)；9年随防时微量白蛋白尿和大量白蛋白尿发生的相对风险分别下降24%(P=0.00062)和33%(P=0.026，1b级)。ADVANCE对病程较长，合并心血管高危因素的2型糖尿病患者采用以格列齐特缓释片为基础的降糖治疗，主要微血管事件减少14%(P=0.01)，肾脏事件减少21%(P=0.006，1b级)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列齐特缓释片", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)糖尿病肾病临床诊断依据", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病足的表现为感染、溃疡和坏疽。溃疡依据病因可分为神经性、缺血性和混合性溃疡；坏疽的性质可分为湿性坏疽、干性坏疽和混合性坏疽3种类型。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感染", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "溃疡", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "坏疽", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "接受肥胖与糖尿病外科手术患者均需终身随访，临床实践中不少医疗机构对接受减重代谢手术的病人缺少规律的随访，致使手术的安全性和有效性缺乏保障。指南确定术后1年内应至少进行4次随访，建议门诊随访，另需更多次的电话或其他方式随访，术后1个月起应对糖尿病改善进行较为完善的评估，包括血糖、糖化血红蛋白、胰岛素、C肽等，术后6个月起应对血生化、营养状况及心理、精神评估进行完善，内容应包括骨密度、维生素及微量元素水平，同时监测是否有手术并发症，进行必要的干预。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "减重代谢手术", "subject_type": "临床手术", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "减重代谢手术", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "糖化血红蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "胰岛素", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "C肽", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐12：T2DM血脂异常患者的调脂治疗在血脂达标后，仍需长期维持治疗(推荐；A级证据)。T2DM血脂异常患者的调脂治疗在血脂达标后，仍需长期维持治疗(推荐；A级证据)。已有证据表明，长期调脂治疗可给患者带来更大的获益。由于炎症和不稳定状态会持续一段时间，如T2DM患者发生了急性冠状动脉综合征(ACS)事件后，他汀类药物强化治疗应至少坚持2年，此后用有效剂量长期治疗。而在治疗期间，需对T2DM患者加强健康教育与管理，强调血脂异常的危害、达标及长期治疗的获益等.提高患者长期治疗依从性。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠状动脉", "subject_type": "患病部位", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2年", "subject_type": "持续时间", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "推荐起始剂量为40mg，每日1次。若2周后，血尿酸水平仍不低于360μmol/L，建议剂量增至80mg，每日1次。②给药时，无需考虑食物和抗酸剂的影响。③轻、中度肾功能不全(eGFR30~89ml/min)的患者无需调整剂量。④对于CKD4期及以上患者，已有多项研究示非布司他的有效性及安全性，建议起始剂量为20mg，每日1次。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "4期", "subject_type": "分期分型", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非布司他", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "非布司他"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "起始剂量为20mg", "subject_type": "用药剂量", "object": {"@value": "非布司他"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病视网膜病变是导致糖尿病患者失明的主要原因。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.失代偿性肝硬化及急性肝功能哀竭是他汀类药物应用禁忌证。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "失代偿性肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "失代偿性", "subject_type": "分期分型", "object": {"@value": "失代偿性肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "失代偿性肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "急性肝功能哀竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "急性肝功能哀竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "急性肝功能哀竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.饮食管理：饮食管理旨在根据中国糖尿病患者的饮食特点，纠正患者的不良饮食习惯，帮助患者树立科学的饮食观念，学会并应用健康的饮食方法。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "a.西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病的患者时需要根据肌酐清除率调整剂量。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "中、重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "中、重度", "subject_type": "分期分型", "object": {"@value": "中、重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "中、重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐清除率", "subject_type": "检查指标", "object": {"@value": "中、重度肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐清除率", "subject_type": "检查指标", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析", "subject_type": "非药治疗", "object": {"@value": "终末期肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "⑦利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者(MEN2)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺髓样癌(MTC)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型多发性内分泌肿瘤综合征患者(MEN2)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "早期良好的血糖控制是降低远期并发症风险的重要手段。对于血糖较高伴高血糖症状的新诊断糖尿病患者，口服降糖药很难在短期内使血糖得到满意的控制，可使用口服降糖药与基础胰岛素联合治疗，使血糖达标，并部分恢复胰岛β细胞功能。对于已使用口服降糖药治疗的患者，当1~2种较大剂量的口服降糖药规范治疗3个月以上血糖仍未达标时，也可联合使用基础胰岛素以进一步控制血糖。对15项随机对照研究进行的汇总分析也提示，使用二甲双胍和/或磺脲类药物血糖控制不佳的T2DM患者，起始基础胰岛素治疗后，能有效控制血糖，且不会增加严重低血糖发生的风险。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "因此，本共识将血尿酸水平>420μmol／L(7mg／dl)定义为HUA", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "格列奈类：为非磺脲类短效胰岛素促泌剂，以降低餐后血糖为主，需餐前服用，起效快、半衰期较短。在相同降糖效力的前提下，格列奈类药物低血糖的风险较磺脲类药物低(A)。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "餐前服用", "subject_type": "用药方法", "object": {"@value": "格列奈类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类药物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "预混胰岛素能同时提供基础及餐时胰岛素，方案简便、易操作，在中国糖尿病患者中应用广泛。临床医生要根据患者的具体情况综合考虑，包括生活方式、方案的简便程度，长期依从性，血糖监测及低血糖发生等多种因素，制定个体化的胰岛素治疗方案。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "预混胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖监测", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "随着人们生活方式的改变和社会人口老龄化进程的加剧，糖尿病正成为一种全球范围内的慢性流行性疾病。据国际糖尿病联盟估计，至2030年，世界范围内2型糖尿病患者数量将达到5.92亿。糖尿病的管理不仅要实现理想的血糖控制，更要通过良好的代谢控制达到预防慢性并发症、提高患者生活质量及延长患者寿命的目的。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "合理把握胰岛素启动治疗时机。新诊断2型糖尿病患者HbA1c≥9.0%同时合并明显临床症状，或合并严重并发症，2种或2种以上口服降糖药次大剂量治疗3个月后仍不达标者(HbA1c≥7.0%)，应启动胰岛素治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.围手术期患者：高血糖会增加感染发生率，延迟伤口愈合，因此对于择期手术的患者，手术前血糖控制在FPG<7.8mmol/L，2hPG<10.0mmol/L。对于血糖长期升高者、特殊手术患者等需建立个体化目标。围手术期需使用胰岛素控制血糖，入院前口服降糖药的患者，接受小手术的术前当晚及手术当天应停用口服降糖药，接受大中手术则应在术前3天停用口服降糖药，均改为胰岛素治疗。术前和术后可正常饮食的高血糖患者可采用基础联合餐时胰岛素方案，大中型手术术中需要静脉使用胰岛素。对于常规(非心脏)手术患者，基础联合餐时方案相比仅使用短效或速效胰岛素的方案血糖控制更佳、围手术期并发症更少。入院前已使用胰岛素者，手术日停用早餐前短效/速效胰岛素，继续使用基础胰岛素。长效胰岛素在手术当日早晨予常规剂量的50%~100%；中效胰岛素如为晚间注射，术前1d予常规剂量的75%，手术当日早晨予常规剂量的50%~75%；预混胰岛素在手术当日早晨应更换为基础胰岛素，剂量为预混胰岛素中的中效成分的50%~75%。大中型手术术后病情稳定、恢复正常饮食者可予胰岛素皮下注射。一般起始总剂量为0.4~0.5U(kg·d)，年龄≥70岁或eGFR≤60ml/min者减量至0.2~0.3U/(kg·d)，其中，基础和餐时胰岛素各占50%。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "2hPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "晚间注射", "subject_type": "用药方法", "object": {"@value": "中效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "皮下注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.4~0.5U(kg·d)", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "0.2~0.3U/(kg·d)", "subject_type": "用药剂量", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "沙格列汀的适应证用于2型糖尿病。单药治疗：可作为单药治疗，在饮食和运动基础上改善血糖控制；联合治疗：当单独使用盐酸二甲双胍血糖控制不佳时，可与盐酸二甲双胍联合使用，在饮食和运动基础上改善血糖控制。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "目前推荐的控制目标：血尿酸(SUA)≤360μmol/L(对于有痛风发作的患者，SUA<300μmol/L)(I)。SUA干预治疗切点：男性>420μmol/L，女性>360μmol/L(I)。生活方式(低嘌呤饮食，多饮水)未能控制达标者，应该服用降尿酸药物(D)。老年人推荐服用抑制嘌呤合成类药物(别嘌呤醇，非布司他)，逐步降低血尿酸水平至目标值(II)。如用促尿酸排出的药物苯溴马隆，需注意关注肾功能[肌酐清除率(Ccr)<60ml/min，苯溴马隆≤50mg/d]的变化和碱化尿液，可辅用碳酸氢钠(小量多次)维持尿pH在6.5左右(6.2~6.9)(c)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸(SUA)", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "SUA", "subject_type": "检查指标", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "≤50mg/d", "subject_type": "用药剂量", "object": {"@value": "苯溴马隆"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "小量", "subject_type": "用药剂量", "object": {"@value": "碳酸氢钠"}, "object_type": {"@value": "药品名称"}}]}
{"text": "常用口服降糖药的药代动力学特征及其在T2DM合并CKD人群中应用的临床证据以及适用人群见图1及表3。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "三、T2DM合并ASCVD患者的血糖管理策略和控制目标", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "②妊娠期：无论是妊娠期糖尿病还是糖尿病合并妊娠，当通过饮食治疗血糖不能得到满意控制时，均需起始胰岛素治疗。由于人胰岛素不通过胎盘屏障，因此NPH在妊娠期间使用不受限制。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "饮食治疗", "subject_type": "非药治疗", "object": {"@value": "妊娠期糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "妊娠期糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基于ASCVD危险程度的分层管理策略是当前血脂管理的总体趋势，因此，全面评估ASCVD危险度是T2DM患者进行血脂管理的前提。在确诊T2DM后，应对患者的血脂水平、所具有的心血管危险因素及临床疾患等进行综合评估，并根据评定结果指定相应的血脂管理目标和治疗措施（推荐：C级证据）。值得关注的是，虽然T2DM患者的血脂谱特征是LDL-C正常或轻度升高，但小而致密的LDL颗粒数量增加。事实上，小而密LDL颗粒更容易被氧化形成过氧化脂质，易通过非受体通路摄取，被单核-巨噬细胞的清道夫受体识别、吞噬，形成泡沫细胞，促进ASCVD的发生，具有很强的致ASCVD作用。UKPDS研究结果也显示，LDL-C是T2DM患者发生冠心病和心肌梗死的首要预测因素，LDL-C每上升1mmol/L，冠脉事件发生率增加57%。胆固醇治疗试验（CTT）协作组的meta分析结果也显示，LDL-C每降低1.0mmol/L分别显著下降主要血管事件、心血管死亡和缺血性卒中事件风险达21%、13%和21%。由此证明，T2DDM患者降低LDL-C心血管获益确切。低HDL-C水平往往与TG水平升高相关，也是T2DM患者常见的血脂异常。而靶向升高HDL-C治疗药物的循证证据远远不如他汀类药物充分。因此，当前各糖尿病指南中虽然建议T2DM患者全面控制血脂，但LDL-C仍是首要的降脂治疗目标（表1）。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂水平", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "小而致密的LDL颗粒", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "小而密LDL颗粒更容易被氧化形成过氧化脂质", "subject_type": "患病病因", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "易通过非受体通路摄取", "subject_type": "患病病因", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "被单核-巨噬细胞的清道夫受体识别、吞噬，形成泡沫细胞", "subject_type": "患病病因", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心肌", "subject_type": "患病部位", "object": {"@value": "心肌梗死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠脉事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "冠脉", "subject_type": "患病部位", "object": {"@value": "冠脉事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "缺血性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管死亡"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "缺血性", "subject_type": "分期分型", "object": {"@value": "缺血性卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DDM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG水平", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "为了及早发现T2DM患者的血脂异常，在确诊T2DM的同时均应检测患者的空腹血脂谱(包括TG、TC、HDL-C和LDL-C)(推荐；E级证据)，根据基线血脂水平以制定相应的监测策略(图1)：对于血脂位于正常范围内的患者，如果无其他心血管风险，在T2DM治疗过程中每年至少要进行1次血脂谱的检测；如果伴有多重心血管风险因素(男性≥40岁或绝经期后女性、吸烟、肥胖和早发缺血性心血管病家族史等).则在诊断T2DM后每3个月监测血脂谱1次。对于合并血脂谱异常的T2DM患者，则在起始生活方式干预和药物治疗，以及药物剂量调整期间每4~12周监测1次血脂谱，此后则建议每3~12个月监测1次血脂谱。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "空腹血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TC", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "早发缺血性心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂谱", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "HUA促进缺血性卒中的发生及不良预后，而在神经退化行性疾病如阿尔茨海默病和帕金森病等疾病中，观察到血尿酸升高具有保护作用。尿酸与神经系统疾病间的内再联系有待进一步探索。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸", "subject_type": "检查指标", "object": {"@value": "神经系统疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "慢性肾脏病是指肾脏结构或功能异常持续超过3个月,其诊断标准见表1。肾小球滤过率(GFR)是评价肾脏功能的重要指标之一，我国估算肾小球滤过率(eGFR)课题协作组改良简化肾脏病饮食改良 (modification of diet in renal disease，MDRD)方程，制定了适合我国慢性肾脏病患者的eGFR的评估公式。目前国内外大部分指南根据GFR来进行慢性肾脏病的肾功能分期(表2)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在二肽基肽酶4(DPP-4)抑制剂中进行的3项随机、双盲、安慰剂对照的CVOT均显示，DPP-4抑制剂既不增加也不降低心血管事件发生风险。评估T2DM患者中西格列汀心血管安全性(TECOS)研究纳入14671例有心血管病史的T2DM患者，中位随访时间为3年。结果显示，在常规降糖治疗基上，与安慰剂组相比，西格列汀组首要心血管事件复合终点(3终点MACE+不稳定型心绞痛住院)的风险达到非劣效性标准(HR 0.98，95%CI 0.88~1.09)。且不增加心力衰竭住院风险。评价沙格列汀在糖尿病患者中的心血管结局(SAVOR-TIMI53)研究纳入16492例伴有心血管疾病或心血管危险因素的T2DM患者，中位随访时间为2.1年。结果显示，在常规降糖治疗基础上，与安慰剂组相比，沙格列汀组3终点MACE的风险达到非劣效性标准(HR 1.00，95%CI 0.89~1.12)，但心力衰竭住院相对风险增加27%(P=0.007)。阿格列汀与标准治疗在T2DM合并ACS患者中心血管结局比较(EXAMINE)研究在5380例既往15~90d内发生过ACS的T2DM患者中评估阿格列汀的心血管安全性，中位随访时间为18个月。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "西格列汀", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "不稳定型心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "不稳定型", "subject_type": "分期分型", "object": {"@value": "不稳定型心绞痛"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "沙格列汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "ACS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿格列汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "③每日3次方案：预混胰岛素每日2次治疗后HbA1c≥7.0%的患者；血糖控制不达标，需要基础 +餐时胰岛素强化治疗，但不愿意接受该治疗方案的患者。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "推荐16：在服用他汀类药物期间出现肌肉不适或无力症状以及排褐色尿时，应及时监测肌酸激酵(CK)，注意排除甲状腺功能低下、过度运动等导致的肌肉症状和/或肌酶升高。如果发生或高度怀疑肌炎，应立即停止他汀治疗。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "肌肉不适", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "无力", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "排褐色尿", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肌炎", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能低下"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肌肉", "subject_type": "患病部位", "object": {"@value": "甲状腺功能低下"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酶", "subject_type": "检查指标", "object": {"@value": "甲状腺功能低下"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "应避免使用可能加重自主神经病症状的药物。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "自主神经病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "我国糖尿病患者血糖总体控制水平不理想，在中老年(年龄>45岁)人群的2项全国多省市糖尿病患者调查中，以HbA1c<6.5%为标准，达标率分别为20.3%(2009年)和16.8%(2010年)(C)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "在糖尿病足的药物治疗中，要重视综合治疗。糖尿病足常分为3种类型，即神经型、缺血型和神经缺血型(也叫混合型)。研究发现，我国糖尿病足以混合型为主，其次为缺血型，而单纯神经型比较少见。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "神经型", "subject_type": "分期分型", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "缺血型", "subject_type": "分期分型", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "神经缺血型(也叫混合型)", "subject_type": "分期分型", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "混合型", "subject_type": "分期分型", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "缺血型", "subject_type": "分期分型", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "单纯神经型", "subject_type": "分期分型", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "但是，医疗保障差的人群总花销并不比平均水平低，这主要是因为忽视糖尿病治疗导致血糖过低或过高，引起相关疾病发生而入院诊治。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.降脂药物的选择：研究表明他汀类药物可减少糖尿病血管疾病的发生率和肾功能减退，建议所有糖尿病患者均应首选口服他汀类药物，以TG升高为主时可首选贝特类降脂药。2型糖尿病患者常见混合性高脂血症。单一降脂药大剂量时不良反应增加，为了提高调脂治疗的达标率，往往需不同类别调脂药联合应用。他汀类和贝特类联用：混合性高脂血症经单用他汀类或贝特类未达标者，可考虑两药联合治疗。尽管目前有证据表明两药合理联用是安全的(ACCORD已经证明是安全的)，但除非特别严重的混合性血脂异常，一般应单药治疗；必要时谨慎联合，但剂量应小；两药分开时间服用；他汀类和贝特类联用时，首选非诺贝特。有以下特殊情况者慎用，包括老年、严重肝肾疾病、甲状腺功能减退等，并严密监测和随访，一旦发现异常，及时停药。他汀类和依折麦布联用：单用他汀类调脂药治疗后LDL-C仍未达标者，可考虑他汀类和依折麦布联用。现有证据表明依折麦布和小剂量他汀类联合应用比单独增加他汀类剂量能更好地改善血脂紊乱，且安全性好。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "糖尿病血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "TG", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类降脂药", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "混合性", "subject_type": "分期分型", "object": {"@value": "混合性高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "混合性", "subject_type": "分期分型", "object": {"@value": "混合性高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "混合性高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类", "subject_type": "药品名称", "object": {"@value": "混合性高脂血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "混合性", "subject_type": "分期分型", "object": {"@value": "混合性血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "混合性血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "贝特类", "subject_type": "药品名称", "object": {"@value": "混合性血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "混合性血脂异常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "甲状腺", "subject_type": "患病部位", "object": {"@value": "甲状腺功能减退"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "依折麦布", "subject_type": "药品名称", "object": {"@value": "血脂紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "血脂紊乱"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类", "subject_type": "药品名称", "object": {"@value": "血脂紊乱"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.2 肾功能不全的T2DM患者是否可以使用磺脲类药物? ", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(二)糖尿病肾病的筛查和肾功能评价", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "本共识建议，对于2型糖尿病患者，以下情况应给予胰岛素治疗：(1)急性并发症或严重慢性并发症；(2)应激情况(感染、外伤、手术等)；(3)严重合并症，肝肾功能不全；(4)妊娠期间。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.心血管病变(冠心病、心律失常、心力衰竭)：对于老年糖尿病患者应早期开始干预和治疗心血管病变的危险因素，包括在糖尿病及高血压前期即开始管理、生活方式干预、及时启动降LDL-C治疗等综合心血管危险因素管理措施(A)。对糖尿病合并高血压和/或高LDL-C血症者应关注血管病变的筛查，颈动脉彩色多普勒超声检查为简便易行、特异性好的筛查方法(III)。有异常症状者适时行冠状动脉CT血管造影(CTA)可较早发现病变及时处置(III)。老年糖尿病患者因伴存心脏自主神经病变，可发生乏力、心悸、水肿等不典型症状或无症状心肌梗死，易合并心律失常或心力衰竭，可导致心源性猝死(C)。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心律失常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "颈动脉彩色多普勒超声检查", "subject_type": "检查方法", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "颈动脉彩色多普勒超声检查", "subject_type": "检查方法", "object": {"@value": "高血压"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "颈动脉彩色多普勒超声检查", "subject_type": "检查方法", "object": {"@value": "高LDL-C血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "颈动脉彩色多普勒超声检查", "subject_type": "检查方法", "object": {"@value": "血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "乏力", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "心悸", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "水肿", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "无症状心肌梗死", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脏自主神经病", "subject_type": "患病部位", "object": {"@value": "心脏自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "乏力", "subject_type": "临床表现", "object": {"@value": "心脏自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "心悸", "subject_type": "临床表现", "object": {"@value": "心脏自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "水肿", "subject_type": "临床表现", "object": {"@value": "心脏自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "无症状心肌梗死", "subject_type": "临床表现", "object": {"@value": "心脏自主神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心律失常"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病的诊断分2步。首先确定是否符合糖尿病的诊断标准，然后再分型。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "”目前，SGLT-2抑制剂未被批准用于1型糖尿病；儿童青少年及孕妇和哺乳期妇女中无使用SGLT-2抑制剂的数据，故暂不推荐在此类人群中使用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)抗凝血药物(肝素、低分子肝素及口服抗凝血药物)：月前没有明确的证据支持在糖尿病足前期的间歇性跛行阶段应用抗凝血治疗。与单用阿司匹林相比，在严重肢体缺血患者，低分子肝素联合阿司匹林能显著降低血管腔内微创治疗(球囊扩张及支架植入)的糖尿病足患者的血管闭塞/再狭窄(高达85%)(OR=0.15，95%CI：0.06~0.42，P=0.0003)；而巴曲酶联合阿司匹林显著降低糖尿病患者的再狭窄(OR=0.28，95%Cl：0.13~0.60)，不伴出血和其他消化道不良事件的显著增加。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "肝素", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "低分子肝素", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "间歇性跛行", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "肢体缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肢体", "subject_type": "患病部位", "object": {"@value": "肢体缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "低分子肝素", "subject_type": "药品名称", "object": {"@value": "肢体缺血"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "血管腔内微创治疗(球囊扩张及支架植入)", "subject_type": "临床手术", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "血管闭塞/再狭窄", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "巴曲酶", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "出血", "subject_type": "不良反应", "object": {"@value": "巴曲酶"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "消化道不良事件", "subject_type": "不良反应", "object": {"@value": "巴曲酶"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "出血", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "消化道不良事件", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "再狭窄", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.下肢运动康复治疗：对于足部皮肤完整的缺血型或神经缺血型患者，运动锻炼能改善间歇性跛行患者的步行距离及行走时间。与安慰剂或常规护理相比较，监督下的运动康复锻炼可显著提高下肢动脉病变患者的最大步行距离[加权均数差 (WMD) =218.01m，95%CI：161.54~274.48m，P<0.00001] 、无痛行走距离(WMD=174.19m，95%CI：130.25~218.13m，P<0.00001) 、6min 步行距离(WMD=42.91m，95%CI：25.41~ 59.41m，P<0.00001)。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "运动锻炼", "subject_type": "非药治疗", "object": {"@value": "间歇性跛行"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动康复锻炼", "subject_type": "非药治疗", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢动脉", "subject_type": "患病部位", "object": {"@value": "下肢动脉病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "e.阿格列汀在肝功能检查结果异常的患者中应慎重使用。如果患者报告发生可能提示肝损伤的症状，迅速进行肝功能检查。如果患者出现具有临床意义的肝酶升高，和肝功能检查异常结果持续或恶化，应停用阿格列汀。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肝功能", "subject_type": "检查方法", "object": {"@value": "肝损伤"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "长期服用他汀类药物可能引起血糖异常和增加新发糖尿病的风险。对13项随机对照临床研究进行的meta分析中，他汀治疗组新发糖尿病风险增加9%。关于他汀类药物的类效应的研究发现，阿托伐他汀、瑞舒伐他汀、辛伐他汀、氟伐他汀在正常人和T2DM患者中都具有类似的对血糖调控的不良影响，而匹伐他汀和普伐他汀对血糖调节具有较中性的作用。目前发现他汀引发新发糖尿病的可能机制有：增加其他致糖尿病的危险因素、损伤胰岛β细胞、降低胰岛素敏感性等。一个遗传学随机试验发现他汀类药物通过抑制HMG-CoA还原酶活性，可引起体重增加，从而增加新发糖尿病的风险。在另一项meta分析中，高剂量他汀治疗比中等剂量他汀增加新发糖尿病的风险12%，提示他汀引发新发糖尿病与剂量相关。但他汀对心血管疾病的总体益处与新发糖尿病风险之比是9：1，他汀类药物对心血管疾病的保护作用远大于新发糖尿病风险。使用中等强度他汀不仅有效降低心脑血管事件，同时安全性和耐受性良好。现有数据表明，如果有在使用他汀类出现血糖不良反应，通常反应小且可通过调整血糖控制方案减弱该反应。而他汀减少有糖尿病风险患者的心血管事件的获益已得到充分肯定。因此，T2DM患者使用他汀治疗期间，着重于通过减轻体重或降糖药物来控制血糖和HbA1c，并提供适当的饮食与运动建议。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "血糖异常", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿托伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "瑞舒伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "辛伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氟伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "匹伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "普伐他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "新发糖尿病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "中等强度他汀", "subject_type": "药品名称", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "心脑血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "血糖不良反应", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "降糖药", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "减轻体重", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(4)糖尿病合并慢性肾脏病患者：糖尿病合并慢性肾脏病，尤其是估算肾小球滤过率(estimated glomerular filtration rate，eGFR)<45mL·min-1(1.73m2)-2的患者，其血糖控制目标应遵循个体化原则，尽量避免低血糖的发生。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率(estimated glomerular filtration rate，eGFR)", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾脏病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)按时、定量进餐及规律运动，预混人胰岛素应在早、晚餐前30min皮下注射，预混胰岛素类似物", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "早、晚餐前30min皮下注射", "subject_type": "用药方法", "object": {"@value": "预混人胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "高血尿酸水平与卒中后早期死亡风险呈正相关，血尿酸水平增高可提示患者卒中后90d预后不良。急性卒患者血尿酸增高是卒中复发的独立危险因素。血尿酸水平可作为急性缺血性卒中患者预后评估的一项指标，预测卒中后死亡及复发的风险。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "高血尿酸水平", "subject_type": "临床表现", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "卒中"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸水平", "subject_type": "检查指标", "object": {"@value": "急性缺血性卒中"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)促纤溶药：蚓激酶是从露天红赤子爱胜蚓中提取的一种含有纤维蛋白溶酶和纤维蛋白溶酶原激活剂的混合物，可用于缺血性心脑血管疾病和糖尿病性周围血管闭塞症。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心脑血管", "subject_type": "患病部位", "object": {"@value": "缺血性心脑血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围血管", "subject_type": "患病部位", "object": {"@value": "糖尿病性周围血管闭塞症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者血糖波动管理专家共识 ", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者血糖水平低于3.9mmol/L(70mg/dI)时，定义为低血糖。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "低血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": ")患者，推荐50mg／d，尿酸性肾石症和重度肾功不全(eGFR<20ml.min-1·1.73m-2)患者禁用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "尿酸性肾石症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者常合并代谢综合征的一个或多个组分，如高血压、血脂异常、肥胖症等，因此糖尿病患者不仅要控制血糖，还要降压、调脂、控制体重，改善生活方式，只有全面达标，才能有效控制糖尿病。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "控制血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "降压", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "调脂", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "控制体重", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "改善生活方式", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病肾病的防治分为三个阶段。第一阶段为糖尿病肾病的预防，对重点人群进行糖尿病筛查，发现糖耐量受损或空腹血糖受损的患者，采取改变生活方式、控制血糖等措施，预防糖尿病及糖尿病肾病的发生。第二阶段为糖尿病肾病早期治疗，出现微量白蛋白尿的糖尿病患者，予以糖尿病肾病治疗，减少或延缓大量蛋白尿的发生。第三阶段为预防或延缓肾功能不全的发生或进展，治疗并发症，出现肾功能不全者考虑肾脏替代治疗。糖尿病肾病的治疗以控制血糖、控制血压、减少尿蛋白为主，还包括生活方式干预、纠正脂质代谢紊乱、治疗肾功能不全的并发症、透析治疗等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "糖耐量受损", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "空腹血糖受损", "subject_type": "发病机制", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "改变生活方式", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "肾脏替代治疗", "subject_type": "非药治疗", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血压", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "透析治疗", "subject_type": "非药治疗", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)微血管并发症：动态血糖监测系统(continuous glucose monitoring system，CGMS)测得的血糖波动与尿微量白蛋白排泄率具有相关性，血糖波动也是糖尿病视网膜病变的相关危险因素。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿微量白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "基于证据总结和专家意见，DPP-4i可用于血管疾病或心血管事件风险的2型糖尿病患者。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "血管", "subject_type": "患病部位", "object": {"@value": "血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管事件"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "正常体能者、老龄体弱者、肢体残障者、智能障碍者分别选择能进行、容易坚持的全身或肢体运动方式。运动前需进行运动安全性评估。结合轻度、中度运动消耗量安排时间，提倡餐后的适量室内活动与每周3~4次的体能锻炼相结合，有利于缓解餐后高血糖，并保持或增强体质。结合有计划的抗阻力运动，如举重物、抬腿保持等可以帮助老年患者延缓肌肉的减少。肥胖者可通过适当增加有氧运动量消耗脂肪储存(B)。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "餐后的适量室内活动", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "每周3~4次的体能锻炼", "subject_type": "非药治疗", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "增加有氧运动量", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.运动管理：运动锻炼在糖尿病患者的全面管理中占重要地位。规律运动可增加胰岛素敏感性，有助于控制血糖，减少心血管危险因素.减轻体重，提升幸福感。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "运动管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "运动锻炼", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.格列奈类促泌剂：格列奈类促泌剂直接刺激胰岛β细胞分泌胰岛素，其最大特点是改善早相分泌，起效快、作用时间短，以降低餐后血糖为主，且低血糖风险小、受肾功能影响小(3b级)。一般需1日多次服用。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列奈类促泌剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1日多次", "subject_type": "用药频率", "object": {"@value": "格列奈类促泌剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病患者在其长期的治疗过程中涉及到“家—医院—家“的一体化管理，糖尿病患者绝大多数时间需要在家和门诊进行调整和管理血糖，但许多情况下可能需要住院进行短期血糖管理和优化治疗、并发症筛查和应激状态的控制等，尤其在需要起始胰岛素治疗的情况下。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "并发症筛查", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "应激状态的控制", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "包括拉布立酶(rasburicase)和普瑞凯希(pegloticase)。拉布立酶时一种重组尿酸氧化酶，主要用于预防和治疗血液系统恶性肿瘤患者的急性HUA，尤其适用于放化疗所致的HUA。使用拉布立酶可诱发抗体生成而使疗效下降。普瑞凯希是一种聚乙二醇重组尿酸氧化酶，适用于大部分难治性痛风，可用于其他药物疗效不佳或存在禁忌证的成年难治性痛风患者。普瑞凯希主要不良反应包括严重心血管事件、输液反应和免疫原性反应。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "拉布立酶", "subject_type": "药品名称", "object": {"@value": "急性HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "普瑞凯希", "subject_type": "药品名称", "object": {"@value": "难治性痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "普瑞凯希", "subject_type": "药品名称", "object": {"@value": "成年难治性痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重心血管事件", "subject_type": "不良反应", "object": {"@value": "普瑞凯希"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "输液反应", "subject_type": "不良反应", "object": {"@value": "普瑞凯希"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "免疫原性反应", "subject_type": "不良反应", "object": {"@value": "普瑞凯希"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "放化疗", "subject_type": "患病病因", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "不同国家的研究显示PCOS患者肥胖的发生率在30%~70%。系统性综述表明，与正常体重的PCOS女性相比，肥胖PCOS患者所有代谢和生殖的指标(除多毛症外)，包括性激素结合球蛋白(sex hormone-binding globulin)下降，总睾酮、空腹血糖、空腹胰岛素增加和血脂升高。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "性激素结合球蛋白(sex hormone-binding globulin)", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "总睾酮", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹胰岛素", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血脂", "subject_type": "检查指标", "object": {"@value": "PCOS"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "如果怀疑发生了腹腺炎，应该立即停用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "腹腺", "subject_type": "患病部位", "object": {"@value": "腹腺炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病是ASCVD的独立危险因素，不同类型的高血糖状态，包括空腹血糖(FPG)、餐后血糖(PPG)以及HbA1c的升高，均是ASCVD的危险因素。因此，血糖管理是T2DM合并ASCVD患者综合管理策略中的重要组成部分，以下将对此进行详细阐述。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血糖(FPG)", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖(PPG)", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "ASCVD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(3)心血管疾病", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "三、心血管疾病合并糖尿病患者的血糖控制目标", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "与1型糖尿病不同，2型糖尿病一经诊断，就要进行相关并发症、合并症的评估。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·新诊断1型糖尿病；", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4级：严重感染已造成骨质破坏，骨髓炎，骨关节破坏或已形成假关节，Charcot关节病，部分足或趾发生湿性或干性严重坏疽或坏死。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "骨质破坏"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "骨髓炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "骨关节破坏"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "假关节"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "Charcot关节病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "感染", "subject_type": "患病病因", "object": {"@value": "足或趾发生湿性或干性严重坏疽或坏死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨髓", "subject_type": "患病部位", "object": {"@value": "骨髓炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "骨关节", "subject_type": "患病部位", "object": {"@value": "骨关节破坏"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "假关节"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "Charcot关节病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "足或趾发生湿性或干性严重坏疽或坏死"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "趾", "subject_type": "患病部位", "object": {"@value": "足或趾发生湿性或干性严重坏疽或坏死"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.二甲双胍能否预防糖尿病：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2型糖尿病(T2DM)患者合并血脂异常，可进一步增加大血管和微血管并发症的风险。为了进一步做好T2DM患者的血脂管理工作，中华医学会内分泌学分会曾于2011年颁布了《中国2型糖尿病合并血脂异常防治专家共识》。近年来，一系列新研究结果的发表、新指南的颁布，促使了血脂异常管理理念进一步发展。为了进一步优化我国T2DM患者的血脂管理，为临床医生提供更为科学合理的诊疗建议，中华医学会内分泌学分会根据中国患者的疾病特点，参考国内外新的循证证据和指南，对2011年版的《中国2型糖尿病合并血脂异常防治专家共识》进行修订，以更好地规范我国T2DM患者的血脂管理，预防动脉粥样硬化性心直管疾病(ASCVD)的发生。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "大血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "2型糖尿病(T2DM)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心直管", "subject_type": "患病部位", "object": {"@value": "动脉粥样硬化性心直管疾病(ASCVD)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "符合两种疾病诊断的患者即可按照T2DM合并肥胖进行管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.肠内/肠外营养患者：接受肠内/肠外营养的住院糖尿病患者如血糖得不到满意控制，可增加并发症和死亡风险。无论是否诊断为糖尿病，接受人工营养的患者血糖>7.8mmol/L即可起始胰岛素治疗。已接受胰岛素治疗的大部分患者血糖控制目标推荐7.8~10.0mmol/L，更为严格的目标，如6.1~7.8mmol/L适用于某些需要严格控制血糖的重症患者。持续肠内营养采用基础联合餐时方案(每日1~2次基础胰岛素联合每4~6h一次短效/速效胰岛素)，基础胰岛素按0.15~0.25U/(kg·d)起始。接受肠外营养的糖尿病患者可根据7~10U/100g葡萄糖的比例酌情添加胰岛素，皮下胰岛素注射也可作为补充。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1~2次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每4~6h一次", "subject_type": "用药频率", "object": {"@value": "短效/速效胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "大多数患者对他汀类的耐受性良好。常见不良反应包括头痛、失眠、抑郁、以及消化不良、腹泻、腹痛、恶心等消化道症状，通常较轻且短暂.常不需要特殊治疗。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "头痛", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "失眠", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "抑郁", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "消化不良", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹泻", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "腹痛", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "恶心", "subject_type": "不良反应", "object": {"@value": "他汀类"}, "object_type": {"@value": "药品名称"}}]}
{"text": "磺脲类药物改善高血糖的机制包括：①刺激胰岛β细胞分泌胰岛素，包括依赖KATP通道和不依赖KAT P通道刺激胰岛β细胞分泌胰岛素。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制(表2)。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4抑制剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "早期的磺脲类药物以甲苯磺丁脲和氯磺丙脲为代表，由于甲苯磺丁脲增加T2DM患者心血管事件的发生风险，氯磺丙脲作用时间过长易导致低血糖等原因，临床上已基本淘汰。新一代磺脲类药物具有降糖作用强、不良反应少等优势，包括格列美脲、格列齐特、格列吡嗪、格列喹酮、格列本脲(易导致低血糖临床较少使用)等。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "磺脲类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲苯磺丁脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲苯磺丁脲", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "心血管事件", "subject_type": "不良反应", "object": {"@value": "甲苯磺丁脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列美脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列齐特"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列吡嗪"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}]}
{"text": "肾功能改变是糖尿病肾病的重要表现，反映肾功能的主要指标是GFR，根据GFR和其他肾脏损伤证据可进行慢性肾病(CKD)的分期(表2)。横断面调查结果显示，部分糖尿病患者无尿白蛋白排泄异常，但已经存在GFR下降，提示尿白蛋白阴性者也可能存在肾病，GFR可作为糖尿病肾病的诊断依据之一。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾功能", "subject_type": "检查方法", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "慢性肾病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾脏", "subject_type": "患病部位", "object": {"@value": "慢性肾病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "慢性肾病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肾病(CKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白", "subject_type": "检查指标", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "GFR", "subject_type": "检查指标", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "中国2型糖尿病合并肥胖综合管理专家共识", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国外研究提示，PK可以抑制血管增生，有利于控制糖尿病患者视网膜病变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "视网膜病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)肝肾功能不全", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "Elrick等发现，在血糖变化水平相同的情况下，与静脉注射葡萄糖相比，口服葡萄糖可引起更多的胰岛素分泌，这种现象被称为“肠促胰素效应”。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "静脉注射", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "葡萄糖"}, "object_type": {"@value": "药品名称"}}]}
{"text": "中国人群血脂控制现状不容乐观，据研究显示，我国人群血清总胆固醇及低密度脂蛋白胆固醇水平增高，如无有效的干预措施，在不久的将来，动脉硬化性心血管疾病的患病率将飞速增长。CCMR-3B研究对全国104家医院的25817例中国T2DM门诊患者进行了调查，结果发现42%的T2DM忠者合并血脂异常，其中仅有55%的患者接受了调脂治疗。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "动脉硬化性心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血清总胆固醇及低密度脂蛋白胆固醇水平", "subject_type": "检查指标", "object": {"@value": "动脉硬化性心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "动脉硬化性心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂", "subject_type": "检查方法", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "共识明确提出，正常饮食下，非同日两次空腹血尿酸水平>420μmol/L即可诊断为HUA。同时指出，年龄<25岁、具有痛风家族史的HUA患者需排查遗传性嘌呤代谢异常疾病。关于痛风的诊断既往多采用1977年美国风湿病学会(ACR)痛风分类标准。近年来，关节B超检查和双能CT检查逐渐普及，共识建议采用2015年ACR/欧洲抗风湿病联盟(EULAR)提出的ACR/EULAR痛风分类标准，新标准不仅可用于痛风急性发作期的诊断分类，同时也可应用于间歇期痛风患者的分类，能够真正有效地将痛风从其他疾病中区分出来，从而更好地进行临床研究和药物临床试验。新的标准将影像学诊断纳入评分体系中，体现了对新的影像技术的肯定，但由于关节超声检查易受操作者技术水平影响，超声及双能CT的迅速推广也给痛风的诊断带来新的挑战。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "B超", "subject_type": "检查方法", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "双能CT", "subject_type": "检查方法", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "关节超声", "subject_type": "检查方法", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "超声", "subject_type": "检查方法", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "双能CT", "subject_type": "检查方法", "object": {"@value": "痛风"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "急性发作仅累及1～2个大关节，全身治疗效果不佳者，可考虑关节腔内注射短效糖皮质激素，避免短期内重复使用。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "关节腔内注射", "subject_type": "用药方法", "object": {"@value": "短效糖皮质激素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "很多大型研究表明胰岛素增加体重更明显，比如ADVANCE新近的分析发现用胰岛素体重增加3.3kg，而磺脲服类为0.7kg。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "增加体重", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "5.是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争P450酶，在体内也不降解，面是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此二甲双胍无肝毒性，推荐剂量范围内用药的肝功能正常者，不会造成肝损害。但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能受损"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "同时亚洲人群1型糖尿病患儿抗体阳性率往往比较低，所以自身抗体阴性不能排除胰腺自身免疫的存在。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "抗体阳性率", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "自身抗体", "subject_type": "检查指标", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "此外，改善微循环治疗可能延缓DKD进展；①胰激肽原酶对DKD具有一定疗效，但同样需要高质量的随机对照研究进一步证实；②前列地尔与贝前列素钠可舒张血管平滑肌，发挥扩血管作用，同时通过降低血液黏度、改善红细胞变形能力，从而改善微循环；③文献报道，银杏叶提取物、丹参提取物、黄芪制剂等中药制剂可能发挥一定的肾脏保护作用，但总体上仍缺乏高质量和大型研究数据的支持。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "改善微循环治疗", "subject_type": "非药治疗", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰激肽原酶", "subject_type": "药品名称", "object": {"@value": "DKD"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.早达标：老年糖尿病患者的个性化控制目标包括血糖和非血糖的其他代谢相关指标。已有研究显示，对存在多项心血管危险因素的老年糖尿病患者单纯控制血糖可能得不到心血管获益，而综合防治心血管多危险因素则可能获益(B)。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.3 糖尿病神经病变糖尿病神经病变主要可累及周围神经、自主神经、颅神经，脑及脊髓也可受累，早期表现为神经纤维脱髓鞘和轴突变性、Schwann细胞增生。随着病程进展，表现为轴突变性和髓鞘纤维消失。周围神经病变最常见的症状，诸如麻木、疼痛等感觉异常或者感觉丧失。自主神经受累时，可表现为心血管、胃肠道、泌尿生殖系统和排汗障碍或失调。颅神经病变以动眼神经受损最常见，其次为外展神经、滑车神经、面神经和三叉神经等，常单侧受累，双侧受累少见。脊髓病变以后索损害为主，主要为变性改变。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "自主神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "颅神经", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脑", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脊髓", "subject_type": "患病部位", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "神经纤维脱髓鞘", "subject_type": "临床表现", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "轴突变性", "subject_type": "临床表现", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "Schwann细胞增生", "subject_type": "临床表现", "object": {"@value": "糖尿病神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "周围神经", "subject_type": "患病部位", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "麻木", "subject_type": "临床表现", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "疼痛", "subject_type": "临床表现", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉异常", "subject_type": "临床表现", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "感觉丧失", "subject_type": "临床表现", "object": {"@value": "周围神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "颅神经", "subject_type": "患病部位", "object": {"@value": "颅神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "外展神经", "subject_type": "患病部位", "object": {"@value": "颅神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "滑车神经", "subject_type": "患病部位", "object": {"@value": "颅神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "面神经", "subject_type": "患病部位", "object": {"@value": "颅神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "三叉神经", "subject_type": "患病部位", "object": {"@value": "颅神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "眼神经受损", "subject_type": "临床表现", "object": {"@value": "颅神经病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "脊髓", "subject_type": "患病部位", "object": {"@value": "脊髓病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "变性改变", "subject_type": "临床表现", "object": {"@value": "脊髓病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "后索损害", "subject_type": "临床表现", "object": {"@value": "脊髓病变"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "③围手术期：围手术期需使用胰岛素控制血糖，入院前口服降糖药的患者，接受小手术的术前当晚及手术当天应停用口服降糖药，接受大中手术则应在术前3天停用口服降糖药，均改为胰岛素治疗。术前和术后可正常饮食的高血糖患者可采用基础联合餐时胰岛素方案，大中型手术术中需要静脉使用胰岛素。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "西格列汀与磺脲类药物合用时低血糖风险增加，需适当减少磺脲类剂量；利格列汀与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类剂量；沙格列汀与酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦和泰利霉素等合用时，应将剂量限制为2.5毫克/天。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "低血糖风险增加", "subject_type": "不良反应", "object": {"@value": "西格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖风险增加", "subject_type": "不良反应", "object": {"@value": "磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖风险增加", "subject_type": "不良反应", "object": {"@value": "利格列汀"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖风险增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖风险增加", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "2.5毫克/天", "subject_type": "用药剂量", "object": {"@value": "沙格列汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "2.心力衰竭", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "一、T2DM合并CKD的流行病学", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "流行病学调查显示，我国成年人2型糖尿病患病率为9.7%~11.6%，已成为全球糖尿病患者最多的国家。糖尿病作为慢性终身性疾病，患者生活质量的提高有赖于自身管理。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "自身管理", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.HUA的诊断标准和分型：HUA的诊断标准：嘌呤饮食状态下，非同日2次空腹血尿酸(serum uric acid，SUA)水平，男性>420μmol/L，女性>357μmol/L；没有出现痛风或痛风石时为无症状HUA。HUA的分型诊断，是根据患者低嘌呤饮食5d后，留取24h尿检测尿尿酸水平的结果，分为3型，具体如下：(1)尿酸排泄不良型：尿酸排泄<0.48mg·kg-1·h-1，尿酸清除率<6.2ml/min；⑵尿酸生成过多型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率≥6.2ml/min；(3)混合型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率<6.2ml/min。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "空腹血尿酸(serum uric acid，SUA)", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿尿酸", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸排泄", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿酸清除率", "subject_type": "检查指标", "object": {"@value": "HUA"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "应该说，二甲双胍是真正的糖尿病全程治疗药物，从糖尿病预防到糖尿病前期再到糖尿病的各个阶段。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "非酒精性脂肪性肝病@1.T2DM合并慢性肝炎、非酒精性脂肪性肝病、非酒精性脂肪性肝炎(NASH)、代偿期肝硬化患者在无肝功能不全征象时可安全使用他汀类药，通常无需减小剂量。在糖尿病前期/T2DM患者以及活检证实的NASH患者中采用他汀类药物治疗是安全的。考虑到他们心血管疾病的高风险，对这类人群应该鼓励服用他汀类药物治疗。他汀类药物与治疗感染(如乙型和丙型肝炎)的药物同时使用时，应了解两类药物之间的相互作用，如果存在药物的相互作用，应更换一种与治疗感染无相互影响的他汀类药物或者限制其在最低的剂量使用。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "慢性肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药", "subject_type": "药品名称", "object": {"@value": "慢性肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药", "subject_type": "药品名称", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非酒精性脂肪性肝病", "subject_type": "分期分型", "object": {"@value": "非酒精性脂肪性肝病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪性肝炎(NASH)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药", "subject_type": "药品名称", "object": {"@value": "非酒精性脂肪性肝炎(NASH)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "非酒精性脂肪性", "subject_type": "分期分型", "object": {"@value": "非酒精性脂肪性肝炎(NASH)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药", "subject_type": "药品名称", "object": {"@value": "代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "代偿期", "subject_type": "分期分型", "object": {"@value": "代偿期肝硬化"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "前期", "subject_type": "分期分型", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "糖尿病前期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "NASH"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "乙型和丙型肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "乙型", "subject_type": "分期分型", "object": {"@value": "乙型和丙型肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "丙型", "subject_type": "分期分型", "object": {"@value": "乙型和丙型肝炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "他汀类药物", "subject_type": "药品名称", "object": {"@value": "感染"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "如合并严重痛风(如痛风石、慢性关节炎、痛风频繁发作)患者应严格控制血尿酸水平，治疗目标值<300μmol／L，但不建议180μmol／L以下。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "关节", "subject_type": "患病部位", "object": {"@value": "慢性关节炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.术中持续静脉泵注胰岛素者，建议术后继续泵注24小时以上。机械通气和应用血管活性药物的ICU患者容易出现血糖波动，胰岛素应静脉泵注。", "spo_list": [{"Combined": false, "predicate": "持续时间", "subject": "持续", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "24小时以上", "subject_type": "持续时间", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "静脉泵注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)适用人群：高血糖(FPG>11.1mmol/L，或HbA1c>9%)伴明显高血糖症状的新诊断T2DM患者；1~2种口服降糖药(超重或肥胖患者1~3种口服降糖药)规范治疗3个月以上血糖控制仍未达标者；正在接受预混胰岛素治疗(低于50U/d)的患者血糖控制不佳，频繁发作低血糖者，或对每日2次预混胰岛素注射依从性差者。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "FPG", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "3个月以上", "subject_type": "持续时间", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药剂量", "subject": "低于50U/d", "subject_type": "用药剂量", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(3)血脂控制：2型糖尿病患者每年应至少进行1次血脂检查。接受调脂药物治疗者，根据评估疗效的需要可增加检查次数。目前常用的降脂药物主要包括：他汀类、贝特类、烟酸类、胆酸螯合剂、依折麦布、n-3脂肪酸制剂。在进行降脂药物治疗时，应将降低低密度脂蛋白胆固醇(LDL-C)作为首要目标。未合并冠心病患者的LDL-C<2.6mmol/L，合并冠心病患者的LDL-C<1.8mmol/L。若甘油三酯>5.7mmol/L，可在生活方式干预的基础上使用降低甘油三酯的药物，以降低急性胰腺炎的发生风险。FIELD研究显示，非诺贝特可减缓DR进展，减少激光治疗需求。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "血脂检查", "subject_type": "检查方法", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "非诺贝特", "subject_type": "药品名称", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "LDL-C", "subject_type": "检查指标", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "生活方式干预", "subject_type": "非药治疗", "object": {"@value": "冠心病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "胰腺", "subject_type": "患病部位", "object": {"@value": "急性胰腺炎"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "激光治疗", "subject_type": "非药治疗", "object": {"@value": "DR"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(一)内分泌科住院糖尿病患者的血糖管理", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "4.肾功能不全时肾脏对胰岛素的降解明显减少，同时胰岛素排出速率下降，胰岛素可能在体内蓄积，患者出现氮质血症即血液中的尿素氮达9mmol[/L(25mg/d1)以上、肌酐达178μmol/L以上时，应根据血糖的监测及时减少和调整胰岛素的用量，使血糖维持在适当的范围内。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "肾脏对胰岛素的降解明显减少", "subject_type": "发病机制", "object": {"@value": "氮质血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素排出速率下降", "subject_type": "发病机制", "object": {"@value": "氮质血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素可能在体内蓄积", "subject_type": "发病机制", "object": {"@value": "氮质血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿素氮", "subject_type": "检查指标", "object": {"@value": "氮质血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肌酐", "subject_type": "检查指标", "object": {"@value": "氮质血症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "氮质血症"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题4：DPP-4i联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "DPP-4i", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "儿童青少年肥胖已成为全球性的严重公共卫生问题，随之而来的是儿童青少年2型糖尿病(type 2 diabetes mellitus)发病率的急剧上升。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病(type 2 diabetes mellitus)"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年患者降糖目标应个体化，考虑个人功能状态、共患或伴发疾病，尤其应考虑是否发生过心血管疾血、低血糖、微血管并发症等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "用法及用量：成人起始剂量为每次口服50mg，每日1次，早餐后服用。成人及14岁以上患者每日50~100mg。轻、中度肾功能不全患者(eGFR>60ml/min)无须调整剂量。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "eGFR", "subject_type": "检查指标", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "研究表明，接受高蛋白膳食6个月的肥胖者比接受正常蛋白质饮食者体重下降更明显，1年随诊后高蛋白膳食仍较对照组多降低了10%腹部脂肪。Noakes等证实，采用高蛋白膳食比高碳水化合物膳食的肥胖人群体重下降更多(6.4kg比3.4kg，P=0.035)。当受试者每日允许能量摄入为20kcal/kg时，其蛋白质占总能量的30%，碳水化合物占45%，脂肪占25%，同时补充维生素和钾，12周后体重明显减轻(4.72±4.09)kg，BMI、腰围和腰臀比(WHR)也分别下降(1.87±1.57)kg/m2、(3.73±2.91)cm和(0.017±0.029)。Layman等将健康成年肥胖个体随机分为高蛋白低碳水化合物组(PRO组)和低蛋白高碳水化合物饮食组(CHO组)，4个月后，两组体重减少量虽无明显差别，但是PRO组的机体脂肪(体脂)含量减少更明显；相对于CHO组，PRO组对肥胖者血清中的甘油三酯、高密度脂蛋白胆固醇的改善更明显，并且依从性更高。一项为期2年的实验比较了高蛋白和高碳水化合物饮食在糖尿病超重者的减重效果，结果提示高蛋白膳食可能对存在糖尿病、心血管疾病和代谢综合征风险的患者有帮助。113例中度肥胖患者经过4周的极低能量饮食的减重治疗后，体重降低了5%~10%，而随后6个月采用高蛋白膳食(18%)及正常蛋白饮食(15%)进行体重维持，结果显示高蛋白膳食体重反弹率更低。", "spo_list": [{"Combined": false, "predicate": "非药治疗", "subject": "高蛋白膳食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白膳食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "甘油三酯", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "高密度脂蛋白胆固醇", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白膳食", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白膳食", "subject_type": "非药治疗", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白膳食", "subject_type": "非药治疗", "object": {"@value": "代谢综合征"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心血管", "subject_type": "患病部位", "object": {"@value": "心血管疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "极低能量饮食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "高蛋白膳食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "正常蛋白饮食", "subject_type": "非药治疗", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "《中国2型糖尿病防治指南 (2013年版)》指出，每日1次基础胰岛素或每日1~2次预混胰岛素均可作为胰岛素起始治疗方案，如基础胰岛素或预混胰岛素与口服降糖药联合治疗控制血糖不达标则应将治疗方案调整为多次胰岛素注射(基础+餐时岛素或每日3次预混胰岛素类似物)。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1次", "subject_type": "用药频率", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日1~2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "注射", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "每日3次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素类似物"}, "object_type": {"@value": "药品名称"}}]}
{"text": "注射技术自我管理处方包括：(1)注射技术教育：根据患者注射技术的问题实施个体化教育，需要考虑患者的经济能力、教育水平、年龄、影响操作的其他因素等。(2)胰岛素泵使用教育：胰岛素泵治疗是采用人工智能控制的胰岛素输入装置，通过持续皮下输注胰岛素的方式，最大程度模拟胰岛素的生理性分泌模式，从而达到更好控制血糖的一种胰岛素治疗方法。泵治疗适用于1型糖尿病患者、需要短期胰岛素强化治疗的2型糖尿病以及妊娠期糖尿病等。", "spo_list": [{"Combined": false, "predicate": "用药方法", "subject": "持续皮下输注", "subject_type": "用药方法", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "老年男性2型糖尿病早期肾病患者[尿白蛋白/肌酐比值(ACR)≥30μg/mg，血肌酐(SCr)<177.8μmol/L]经格列喹酮治疗2个月后血糖各指标显著下降，研究结果显示不升高患者尿氮素(BUN)、SCr、ACR。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "尿白蛋白/肌酐比值(ACR)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血肌酐(SCr)", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列喹酮", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "持续时间", "subject": "2个月后", "subject_type": "持续时间", "object": {"@value": "格列喹酮"}, "object_type": {"@value": "药品名称"}}]}
{"text": "膳食纤维可改善餐后血糖代谢和长期糖尿病控制，谷物膳食纤维还可增强胰岛素敏感性。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "膳食纤维", "subject_type": "非药治疗", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "(2)急性尿酸性肾病：急性尿酸性肾病是严重的HUA导致过量尿酸沉积并阻塞肾小管引起的少尿或无尿性急性肾损伤，多见于肿瘤溶解综合征。急性发生尿路梗阻，出现腰痛、少尿或无尿。急性肾血尿酸显著升高(>900μmol／L)应考虑急性尿酸性肾病，确诊常需肾活检，排除小管间质性肾炎等。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性肾损伤"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "尿路", "subject_type": "患病部位", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "腰痛", "subject_type": "临床表现", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "少尿", "subject_type": "临床表现", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "无尿", "subject_type": "临床表现", "object": {"@value": "尿路梗阻"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血尿酸", "subject_type": "检查指标", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查方法", "subject": "肾活检", "subject_type": "检查方法", "object": {"@value": "急性尿酸性肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "小管间质性肾炎"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "临床问题13：GLP-1RA是否可用于伴有非酒精性脂肪肝的2型糖尿病患者的降糖治疗? ", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "GLP-1RA", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "非酒精性脂肪肝"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "对于采取非手术治疗后减重或血糖控制效果不理想的T2DM合并肥胖患者，可以考虑手术治疗。减重手术可以改善T2DM合并肥胖患者的血糖控制，甚至使部分患者糖尿病“缓解”。手术治疗T2DM的前提是患者尚具备足够的胰岛β细胞功能。严格选择患者及适合的手术方式，充分进行术前评估和术前准备，并加强术后随访和营养、运动指导，是提高手术治疗T2DM有效性和安全性的关键。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖控制", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖控制", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "减重手术", "subject_type": "临床手术", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "减重手术", "subject_type": "临床手术", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖控制", "subject_type": "检查指标", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖控制", "subject_type": "检查指标", "object": {"@value": "肥胖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "术后随访", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "非药治疗", "subject": "营养、运动指导", "subject_type": "非药治疗", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "5.二甲双胍是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍本身对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争肝脏P450酶，在体内也不降解，而是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此，二甲双胍无肝毒性，肝功能正常者，接受推荐剂量范围内用药，不会造成肝损害。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肝", "subject_type": "患病部位", "object": {"@value": "肝损害"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "·严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "胃", "subject_type": "患病部位", "object": {"@value": "胃肠道疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肠道", "subject_type": "患病部位", "object": {"@value": "胃肠道疾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "1.了解患者的血糖控制水平：包括总体水平(HbA1c是最好的证据)、实际血糖波动情况(幅度大小和影响因素)、血糖变化的特点(空腹抑或餐后血糖升高为主，短期还是长期高血糖)；影响血糖控制的因素，包括饮食和运动情况、现有降糖药应用(剂量、方法)、低血糖发生的风险等。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹抑或餐后血糖", "subject_type": "检查指标", "object": {"@value": "高血糖"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "第一代磺脲类药物(如氯磺丙脲、妥拉磺脲、甲苯磺丁脲)的药物原型及其活性代谢产物主要依赖肾脏排泄，在CKD患者应用时半衰期延长，低血糖风险明显增加，因此禁用于该类患者，目前此类药物在临床上已基本被淘汰。在第二代磺脲类药物中，格列本脲的半衰期较长，其活性代谢产物约50%经肾脏排泄，可在CKD患者体内积聚，可能引起严重的低血糖，且持续时间超过24h。格列本脲仅可用于CKD1~2期的患者；3~5期禁用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "第一代磺脲类药物", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "第一代磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "氯磺丙脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "氯磺丙脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "妥拉磺脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "妥拉磺脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "甲苯磺丁脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "低血糖", "subject_type": "不良反应", "object": {"@value": "甲苯磺丁脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "第二代磺脲类药物", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重的低血糖", "subject_type": "不良反应", "object": {"@value": "第二代磺脲类药物"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "严重的低血糖", "subject_type": "不良反应", "object": {"@value": "格列本脲"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "格列本脲", "subject_type": "药品名称", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "1~2期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "3~5期", "subject_type": "分期分型", "object": {"@value": "CKD1~2期"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "2.各种治疗方案的特点：目前临床中常见的胰岛素治疗方案有1天1次或2次基础胰岛素联合口服药、1天2次预混胰岛素方案、基础+餐时胰岛素方案。", "spo_list": [{"Combined": false, "predicate": "用药频率", "subject": "1天1次或2次", "subject_type": "用药频率", "object": {"@value": "基础胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1天2次", "subject_type": "用药频率", "object": {"@value": "预混胰岛素"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "用药频率", "subject": "1天2次", "subject_type": "用药频率", "object": {"@value": "基础+餐时胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "糖尿病发病机制与中国2型糖尿病患者特点", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "密切监测别嘌醇的超敏反应。别嘌醇的超敏反应主要发生在最初使用的几个月内，最常见的是剥脱性皮炎。使用噻嗪类利尿剂及肾功能不全是发生超敏反应的危险因素。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "剥脱性皮炎", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "别嘌醇"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "超敏反应", "subject_type": "不良反应", "object": {"@value": "噻嗪类利尿剂"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "其他中药提取物如血塞通注射液、丹红注射液和津力达颗粒等临床上也可用于治疗糖尿病微循环障碍疾病，但缺少长期大样本数据的支持。常用改善糖尿病微循环障碍药物的简要说明见表2和药品说明书。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "血塞通注射液", "subject_type": "药品名称", "object": {"@value": "糖尿病微循环障碍疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "丹红注射液", "subject_type": "药品名称", "object": {"@value": "糖尿病微循环障碍疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "津力达颗粒", "subject_type": "药品名称", "object": {"@value": "糖尿病微循环障碍疾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "微循环障碍", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病患者从计划妊娠至整个孕期，都应进行严格的血糖管理.以减少不良妊娠结局的发生。计划妊娠的糖尿病患者因血糖控制不良或合并严重急、慢性并发症入院时，需要进行以下管理：", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "不良妊娠", "subject_type": "临床表现", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "糖尿病微血管并发症最主要的危险因素是糖尿病病程和高血糖。资料显示，我国糖尿病视网膜病变(diabetic retinopathy，DR)的患病率为24.7%~37.5%，病程<5年者眼底病变患病率为38.0% ~39.0%；病程5~10年者眼底病变患病率为5 0.0%~56.7%；病程>10年者眼底病变患病率增至69.0%~90.0%。目前我国尚缺乏全国性的糖尿病肾脏疾病(diabetic kidney disease，DKD)流行病学调查资料，但就基层而言，2009-2013年的资料提示，我国社区2型糖尿病患者DKD患病率已高达40%左右，我国16.4%的终末期肾病患者由DKD所致。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "微血管", "subject_type": "患病部位", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "糖尿病病程", "subject_type": "患病病因", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "高血糖", "subject_type": "患病病因", "object": {"@value": "糖尿病微血管并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "视网膜", "subject_type": "患病部位", "object": {"@value": "糖尿病视网膜病变(diabetic retinopathy，DR)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "眼底", "subject_type": "患病部位", "object": {"@value": "眼底病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "眼底", "subject_type": "患病部位", "object": {"@value": "眼底病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "糖尿病肾脏疾病(diabetic kidney disease，DKD)"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "终末期", "subject_type": "分期分型", "object": {"@value": "肾病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "降糖同时减轻或不增加体重的降糖药物主要有GLP-1受体激动剂、二甲双胍、α-糖苷酶抑制剂、DPP-4抑制剂和钠-葡萄糖协同转运蛋白2(sodium-glucose cotransporter-2，SGLT-2)抑制剂。其中，GLP-1受体激动剂可显著减轻患者体重。", "spo_list": [{"Combined": false, "predicate": "不良反应", "subject": "减轻患者体重", "subject_type": "不良反应", "object": {"@value": "GLP-1受体激动剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "研究表明2型糖尿病患者的肿瘤风险增加，目前没有胰岛素促泌剂增加肿瘤风险的确切证据。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "2型", "subject_type": "分期分型", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素促泌剂", "subject_type": "药品名称", "object": {"@value": "2型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "血糖波动与糖尿病慢性并发症的关系越来越受到重视，血糖波动控制的重要性将比肩于HbA1c、空腹血糖、餐后血糖控制。未来，血糖波动的评价指标仍需不断地优化、量化，以易于计算，继续寻找基于终点事件的血糖波动指标的切点及血糖波动与终点事件因果关系的证据，都将有助于优化降糖药物治疗策略，使更多的糖尿病患者受益。", "spo_list": [{"Combined": false, "predicate": "检查指标", "subject": "HbA1c", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "空腹血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "餐后血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病慢性并发症"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血糖", "subject_type": "检查指标", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "3.干细胞移植：干细胞目前尚不能作为治疗糖尿病下肢血管病变的常规手段，国内外研究报道干细胞移植治疗下肢血管病变有一定疗效。目前干细胞移植包括自体和异体移植，是最近十多年发展起来的新技术。自体干细胞移植在国内得到一定程度的普及，取得了良好的效果。目前干细胞的来源有骨髓、外周血和改良的骨髓3种方法。自体干细胞至少有2个优点：(1)不存在免疫排斥；(2)没有胚胎干细胞的伦理问题。异体干细胞主要包括脐血、间充质和胚胎干细胞，前两者在临床上已经有比较好的结果。但是限于国家政策，异体干细胞移植需要有一定的资质，目前处于临床研究阶段，有条件的单位可根据情况决定是否选择。此外，干细胞联合凝胶可以修复糖尿病足的创面，临床上技术尚不完全成熟，建议有条件单位要谨慎开展。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "干细胞移植", "subject_type": "临床手术", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床手术", "subject": "干细胞移植", "subject_type": "临床手术", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢血管", "subject_type": "患病部位", "object": {"@value": "下肢血管病变"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "创面", "subject_type": "临床表现", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "国内外主要糖尿病指南均建议，无论对于超重还是体重正常的T2DM患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了该药在糖尿病治疗中的重要地位。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "CKD患者是他汀引起肌病的高危人群，尤其是在肾功能进行性减退或肾小球滤过率(glomerular filtration rale，GFR)<30ml·min-1·1.73m2)时，并且发病风险与他汀剂量密切相关，故应避免大剂量应用。", "spo_list": [{"Combined": false, "predicate": "药品名称", "subject": "他汀", "subject_type": "药品名称", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "肾功能进行性减退", "subject_type": "发病机制", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "肾小球滤过率(glomerular filtration rale，GFR)", "subject_type": "检查指标", "object": {"@value": "CKD"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "肌病", "subject_type": "不良反应", "object": {"@value": "他汀"}, "object_type": {"@value": "药品名称"}}]}
{"text": "二甲双胍：在定期检查心、肾功能的情况下，稳定期的慢性心力衰竭患者可以服用二甲双胍，但因存在乳酸性酸中毒的潜在风险，急性、病情不稳定或住院的心力衰竭患者禁用。", "spo_list": [{"Combined": false, "predicate": "检查方法", "subject": "心、肾功能", "subject_type": "检查方法", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "稳定期", "subject_type": "分期分型", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "慢性", "subject_type": "分期分型", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "慢性心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "乳酸性", "subject_type": "分期分型", "object": {"@value": "乳酸性酸中毒"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "分期分型", "subject": "急性", "subject_type": "分期分型", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心力衰竭"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "【应对】用药期间，如出现和DKA相关的症状，如腹痛、恶心、呕吐、乏力、呼吸困难，需要考虑是否出现DKA并检测血酮和动脉血酸碱度以明确诊断。明确诊断为DKA者，应立即停用SGLT-2抑制剂，并按照传统DKA治疗程序进行治疗。为减少用药期间发生DKA的风险，建议在择期手术、剧烈体力活动(如马拉松)前24小时停用SGLT-2抑制剂，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT-2抑制剂，采用其他合适降糖措施；口服SGLT2抑制剂期间避免过多饮酒及极低碳水化合物饮食。", "spo_list": [{"Combined": false, "predicate": "临床表现", "subject": "腹痛", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "恶心", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "呕吐", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "乏力", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "临床表现", "subject": "呼吸困难", "subject_type": "临床表现", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血酮", "subject_type": "检查指标", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "动脉血酸碱度", "subject_type": "检查指标", "object": {"@value": "DKA"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "用药方法", "subject": "口服", "subject_type": "用药方法", "object": {"@value": "SGLT2抑制剂"}, "object_type": {"@value": "药品名称"}}]}
{"text": "15.减重效果：二甲双胍具有控制体重的作用。研究表明，新诊断T2DM患者二甲双胍单药治疗16周，可使正常(BMI18.5~23.9kg/m2)、超重(BMI24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81及2.92kg(Ⅰ级)，磺脲类、格列酮类和胰岛素治疗伴有体重增加，以二甲双胍为基础的联合治疗减轻上述药物对体重增加的影响。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "T2", "subject_type": "分期分型", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "二甲双胍", "subject_type": "药品名称", "object": {"@value": "T2DM"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "磺脲类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "格列酮类"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "体重增加", "subject_type": "不良反应", "object": {"@value": "胰岛素"}, "object_type": {"@value": "药品名称"}}]}
{"text": "3.手术治疗：应根据创面情况、患者全身状况，适时进行清创术或植皮术等手术治疗，可有效去除坏死组织，尽早封闭创面，显著缩短疗程，避免因长期换药导致下肢废用性肌萎缩、骨质疏松、深静脉血栓及心肺功能下降等并发症。", "spo_list": [{"Combined": false, "predicate": "患病病因", "subject": "长期换药", "subject_type": "患病病因", "object": {"@value": "下肢废用性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "长期换药", "subject_type": "患病病因", "object": {"@value": "骨质疏松"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "长期换药", "subject_type": "患病病因", "object": {"@value": "深静脉血栓"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病病因", "subject": "长期换药", "subject_type": "患病病因", "object": {"@value": "心肺功能下降"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "下肢", "subject_type": "患病部位", "object": {"@value": "下肢废用性肌萎缩"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "深静脉", "subject_type": "患病部位", "object": {"@value": "深静脉血栓"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "心", "subject_type": "患病部位", "object": {"@value": "心肺功能下降"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "肺", "subject_type": "患病部位", "object": {"@value": "心肺功能下降"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "以低嘌呤饮食为主(表1)，严格限制动物内脏产品，海产品和肉类等高嘌呤食物的摄入。富含嘌呤的蔬菜(莴苣、菠菜、蘑菇、菜花等)、豆类及豆制品与HUA及痛风发作无明显相关性，鼓励患者多食用新鲜蔬菜，适量食用豆类及豆制品(肾功能不全者须在专科医生指导下食用）。", "spo_list": [{"Combined": false, "predicate": "患病部位", "subject": "肾", "subject_type": "患病部位", "object": {"@value": "肾功能不全"}, "object_type": {"@value": "疾病名称"}}]}
{"text": "此外，在行血管旁路手术的糖尿病足患者，阿司匹林或阿司匹林联合双密达莫(ASA/DIP)治疗能显著改善移植人工血管的血管通畅率(OR=0.42，95%C：0.22~0.83，P=0.01)。但在自体静脉移植血管中任何时间点均未发现这种效果，而在人造血管移植中的各个时间点都能发现这种益处，包括在移植12个月后(OR=0.19，95%CI：0.10~0.36，P<0.00001)。阿司匹林联合氯毗格雷与阿司匹林比较，所有血管移植物的通畅率在24个月时均无明显差异，组间的截肢或死亡发生率差异无统计学意义，而阿司匹林联合氯吡格雷虽然不增加大出血或致死性出血风险，但增加总的出血风险(OR=2.65，95%CI：1.69~4.15)，包括轻度出血(OR=2.34，95%CI：1.37~4.00)和中度出血(OR=4.13，95%CI：1.37~12.45)。", "spo_list": [{"Combined": false, "predicate": "临床手术", "subject": "行血管旁路手术", "subject_type": "临床手术", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "患病部位", "subject": "足", "subject_type": "患病部位", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "检查指标", "subject": "血管通畅率", "subject_type": "检查指标", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "阿司匹林", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "双密达莫", "subject_type": "药品名称", "object": {"@value": "糖尿病足"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "出血", "subject_type": "不良反应", "object": {"@value": "阿司匹林"}, "object_type": {"@value": "药品名称"}}, {"Combined": false, "predicate": "不良反应", "subject": "出血", "subject_type": "不良反应", "object": {"@value": "氯吡格雷"}, "object_type": {"@value": "药品名称"}}]}
{"text": "(1)1型糖尿病患者因自身胰岛素分泌绝对缺乏，完全或部分需要外源性胰岛素替代以维持体内糖代谢平衡和生存，基础加餐时胰岛素治疗是其首选的胰岛素治疗方案。", "spo_list": [{"Combined": false, "predicate": "分期分型", "subject": "1型", "subject_type": "分期分型", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "发病机制", "subject": "胰岛素分泌绝对缺乏", "subject_type": "发病机制", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}, {"Combined": false, "predicate": "药品名称", "subject": "胰岛素", "subject_type": "药品名称", "object": {"@value": "1型糖尿病"}, "object_type": {"@value": "疾病名称"}}]}
